Skip to main content
. 2013 Aug 6;109(5):1252–1263. doi: 10.1038/bjc.2013.439

Figure 5.

Figure 5

Influence of Pyk2 expression on overall survival of NSCLC patients. (A) Overall survival curves show that patients with high Pyk2 expression have short survival times by analysing 128 primary NSCLC tissues (P<0.001). (B) Patients with high Pyk2 expression show poor overall survival based on an analysis of 47 matched metastatic lymph node tissues (P=0.018). (C, D) In the squamous carcinoma subtype, the patients' overall survival demonstrates no statistically significant difference between the high and low Pyk2 expression groups (P=0.139). In the adenocarcinoma subtype, patients with high Pyk2 expression show short overall survival times (P<0.001). The Pyk2 low expression: score ⩽3; high expression: score ⩾4.